Small molecules as modulators of the proteostasis machinery: Implication in cardiovascular diseases

Eur J Med Chem. 2024 Jan 15:264:116030. doi: 10.1016/j.ejmech.2023.116030. Epub 2023 Dec 7.

Abstract

With the escalating prevalence of cardiovascular diseases, the substantial socioeconomic burden on healthcare systems is intensifying. Accumulating empirical evidence underscores the pivotal role of the proteostasis network in regulating cardiac homeostasis and function. Disruptions in proteostasis may contribute to the loss of protein function or the acquisition of toxic functions, which are intricately linked to the development of cardiovascular ailments such as atrial fibrillation, heart failure, atherosclerosis, and cardiac aging. It is widely acknowledged that the proteostasis network encompasses molecular chaperones, autophagy, and the ubiquitin proteasome system (UPS). Consequently, the proteostasis network emerges as an appealing target for therapeutic interventions in cardiovascular diseases. Numerous small molecules, acting as modulators of the proteostasis machinery, have exhibited therapeutic efficacy in managing cardiovascular diseases. This review centers on elucidating the role of the proteostasis network in various cardiovascular diseases and explores the potential of small molecules as therapeutic agents.

Keywords: Autophagy; Cardiovascular diseases; Molecular chaperones; Proteostasis; Small molecules; Ubiquitin proteasome system.

Publication types

  • Review

MeSH terms

  • Aging
  • Cardiovascular Diseases* / drug therapy
  • Humans
  • Proteasome Endopeptidase Complex / metabolism
  • Proteostasis*
  • Ubiquitin / metabolism

Substances

  • Ubiquitin
  • Proteasome Endopeptidase Complex